Approach to discover T-and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines Natural immunity against obligate and/or facultative intracellular pathogens is usually mediated by both humoral and cellular immunity. The identification of those antigens stimulating both arms of the immune system is instrumental for vaccine discovery. Although high-throughput technologies have been applied for the discovery of antibody-inducing antigens, few examples of their application for T-cell antigens have been reported. We describe how the compilation of the immunome, here defined as the pool of immunogenic antigens inducing T-and B-cell responses in vivo, can lead to vaccine candidates against Chlamydia trachomatis. We selected 120 C. trachomatis proteins and assessed their immunogenicity using two parallel high-throughput approaches. Protein arrays were generated and screened with sera from C. trachomatis-infected patients to identify antibody-inducing antigens. Splenocytes from C. trachomatis-infected mice were stimulated with 79 proteins, and the frequency of antigen-specific CD4 + / IFN-γ + T cells was analyzed by flow cytometry. We identified 21 antibody-inducing antigens, 16 CD4 + /IFN-γ + -inducing antigens, and five antigens eliciting both types of responses. Assessment of their protective activity in a mouse model of Chlamydia muridarum lung infection led to the identification of seven antigens conferring partial protection when administered with LTK63/CpG adjuvant. Protection was largely the result of cellular immunity as assessed by CD4 + T-cell depletion. The seven antigens provided robust additive protection when combined in four-antigen combinations. This study paves the way for the development of an effective anti-Chlamydia vaccine and provides a general approach for the discovery of vaccines against other intracellular pathogens. U nlike extracellular pathogens, for which protective immunity is caused mostly by the elicitation of functional antibodies, immune protection against host cell-invading pathogens usually is mediated by the concerted action of both humoral and cellmediated immunity. Therefore, the development of efficacious vaccines against obligate and facultative intracellular pathogens depends largely upon the ability to identify antigen formulations that induce effective B-and T-cell responses (1-3). Although both genomic and proteomic strategies have been applied successfully to discover B-cell-stimulating vaccines (4-7), the identification of antigens eliciting effector T cells generally is considered less amenable to high-throughput approaches.
In this study we apply a combination of protein array technology and high-throughput analysis of pathogen-specific T cells to identify antigens eliciting antibodies and cell-mediated immunity during infection. As a model system we have focused our attention on Chlamydia trachomatis, an obligate intracellular pathogen representing a serious public health concern worldwide. In developing countries, it accounts for an estimated 85 million ocular infections every year and is the leading cause of infection-induced blindness. In industrialized countries, 92 million sexually transmitted infections are reported annually (8, 9); these infections can cause pelvic inflammatory disease, ectopic pregnancy, and infertility (10) (11) (12) .
Thus there is an urgent need for an effective Chlamydia vaccine. A large body of evidence derived from our understanding of Chlamydia immunity in animal models (13) (14) (15) (16) and in humans (14, 17) indicates that both IFN-γ-producing, Chlamydia-specific CD4 + type 1 T helper (Th1) cells and antiChlamydia antibodies are required to mount a protective immune response. A number of chlamydial proteins eliciting CD4 + T cells and/or antibodies have been described (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . However, with few exceptions, they provide only partial protection in animal models, and, in any case, their protective activity is not comparable with the protective immunity induced by infection. Thus, the identification of protective antigens that could be used either as an alternative to those already characterized or in combination with them is a high priority in Chlamydia vaccine development.
Beginning with the expression and purification of several Chlamydia recombinant proteins, we showed their use in protein microarray and high-throughput analysis of Chlamydia-specific CD4 + T cells to identify antigens eliciting antibodies and cellmediated immunity during infection in experimental animals and human patients. We then mixed the identified antigens in different combinations, some of which protected mice against Chlamydia intranasal challenge, as judged by the substantial reduction of postchallenge Chlamydia infection and acceleration of bacterial clearance.
This study is one of the few in which high-throughput genomic technologies are exploited in parallel to identify bacterial proteins eliciting humoral and/or cell-mediated immunity during natural/experimental infection and to select effective antigen/ adjuvant vaccine combinations. This approach paves the way for the development of vaccines against pathogens for which preventive intervention thus far has been considered extremely difficult to achieve.
Results
Strategy for Discovery of Anti-Chlamydia Vaccine Candidates. Our strategy was based on four major steps (Fig. S1 ). First, we analyzed the C. trachomatis serovar D genome (http://www.ncbi.nlm.
nih.gov/) to identify genes encoding (i) peripheral proteins (predicted to be associated with the outer and inner membrane), (ii) secreted proteins, and (iii) homologs to proteins reported to be involved in virulence or pathogenicity in other bacteria, independent of their localization. Second, 120 selected C. trachomatis proteins were subjected to high-throughput expression and purification (Table S1 ). Third, recombinant proteins were used (i) to generate protein arrays for subsequent analysis of sera from Chlamydia-infected human patients and (ii) to test their ability to stimulate IFN-γ production in spleen-derived CD4 + T cells from C. trachomatis-infected mice. The fourth and final step involved the evaluation of the protective activity of combinations of selected antigens using the Chlamydia muridarum mouse model of lung infection, a model we selected because of its robustness and reproducibility. The selection of C. muridarum as challenge strain required the expression of the C. muridarum proteins that are orthologs to the identified C. trachomatis immunogenic antigens.
Identification of Antibody-Inducing Antigens in C. trachomatisInfected Patients. To define the profile of human antibody response elicited during C. trachomatis infection, we built protein arrays carrying the 120 C. trachomatis recombinant proteins (Table S1 ). The immobilized proteins were probed with 100 sera from culture and microimmunofluorescence-positive (MIF + ) human patients and with 100 serum samples from healthy subjects serologically negative to Chlamydia (MIF − ). Serum reactivity was evaluated by detecting IgGs bound to each protein spot using fluorescently labeled anti-human IgGs.
As shown in Fig. 1A , 23 antigens were recognized by more than 20% of the MIF + sera with fluorescence intensity values >10,000. For 16 of these antigens, both frequency and mean signal intensity values were significantly higher in MIF + sera than in MIF − sera (statistical analysis was carried out using both the two-tailed χ 2 and exact Fisher tests). In particular, 7 of the 16 antigens were recognized almost exclusively by MIF + sera (recognized by <5% of MIF − sera): MOMP (CT681), HtrA (CT823), OmcB (CT443), TARP (CT456), GroEL (CT110), Lcr-E (CT089), and the hypothetical protein CT622. A second group of nine antigens also was recognized by the MIF − sera but with significantly lower frequency and/or fluorescence intensity than in MIF + sera ( Fig. 1 A and B) : YebL (CT415), IncA (CT119), YscJ (CT559), EF-Tu (CT322), RplL (CT316), ArtJ (CT381) and the hypothetical proteins CT049, CT355, and CT589. Among the 23 antigens identified as antibody inducers, 15 had never been described before as immunodominant antigens (Tables S1, S2 , and S3) (19, 20, 23, 25, 26) .
We also assessed whether a similar antibody-recognition pattern occurred in mice infected with C. trachomatis and C. muridarum. Pools of sera from BALB/c mice receiving intranasal infection with C. trachomatis (30 mice) or C. muridarum (50 mice), were tested on the protein chip. Overall, 11 immunoreactive proteins (MOMP, OmcB, HtrA, L7/L12, ArtJ, GroEL, CT622 CT470, CT503, CT647, and CT567) were recognized by sera from C. trachomatis-infected mice. Sera from C. muridarum-infected animals recognized 10 of the 11 proteins (all except CT567) ( Table S2 ). Eight of the 11 proteins (i.e., all except CT470, CT503, and CT647) were recognized both by human and mice sera. Finally, to investigate whether the antibody response could be influenced by the route of infection, pools of sera from 50 BALB/c mice intravaginally infected with C. trachomatis also were tested on the chip. Interestingly, except for L7/L12, all the antigens recognized by sera from intranasally infected animals also were recognized by mice receiving an intravaginal challenge.
In conclusion, sera from MIF + patients recognized a panel of 23 proteins with particularly high intensity and frequency, a large percentage of which also induced antibodies in mice infected with both C. trachomatis and C. muridarum. The difference between the total number of immunogenic antigens in humans and mice probably reflects differences in exposure, as the mice received a single Chlamydia infection, whereas humans are likely to be exposed to repeated infections.
Identification of Antigens Eliciting CD4 Th1 Response in Chlamydia-
Infected Mice. Of the 120 recombinant proteins, 79 (Table S1 ) also were tested for their ability to stimulate IFN-γ production in CD4 + T cells from BALB/c mice that received an intravaginal C. trachomatis infection. Mice were challenged with 10 6 inclusion-forming units (IFUs), and 10 d after challenge splenocytes were prepared and CD4 + T cells were stimulated with 20 μg of LPS-free Chlamydia proteins or unrelated recombinant proteins (Yersinia pestis antigens). As negative control, splenocytes from naïve mice were stimulated with the same amount of proteins. As shown in Fig (19, 20, 27) , OmcB (CT443) (20, 27) , and Enolase (CT587) (18) . To the best of our knowledge, the remaining 16 have not been reported to induce IFN-γ-producing CD4 + T cells during C. trachomatis infection (Tables S2 and S3) .
We next asked whether the IFN-γ-producing CD4 + T cells specific for each of the identified antigens could contribute to the CD4 + T-cell-dependent protective immunity induced by Chlamydia primary infection in mice. To address this question, we used the CD4 + T cells adoptive transfer model (16) , according to which CD4 + T cells from Chlamydia-infected mice protect naive mice from Chlamydia challenge, and we assessed whether CD4 + /IFN-γ + T cells specific for the newly identified antigens were included in a protective elementary body (EB)-specific CD4 + T-cell line. Because C. muridarum gives a more robust and consistent infection than C. trachomatis in mice and induces immune responses mimicking many aspects of C. trachomatis infection in humans (15, 28) , we used the C. muridarum instead of the C. trachomatis model for these experiments. This change required us to produce the recombinant forms of the C. muridarum orthologs of the CD4 + Tcell-inducing C. trachomatis antigens (amino acid identity ranging from 32-99%) ( Table S2 ). The protective cell line (Fig. 2B Inset) was produced by collecting CD4 + T cells from splenocytes of C. muridarum-infected BALB/c mice 30 d after infection and by expanding them through short-term stimulation with heat-inactivated EBs. As shown in Fig. 2B , 11 of the 14 orthologs successfully expressed in Escherichia coli induced IFN-γ production in the protective EB-specific CD4 + T-cell line. The frequency of each antigen-specific T-cell population within the T-cell line pool was at least twofold higher than the mean frequency of five proteins used as negative controls. In addition to MOMP, the 11 positive antigens were HtrA (TC0210/CT823), OmcB (TC0727/CT443), Nqr3 (TC0551/CT279), MAC-perforin (TC0431/CT153), IncA (TC0396/CT119), and the hypothetical proteins TC0284, TC0313, TC0651, TC0890, and TC0106 (CT016, CT043, CT372, CT601, and CT733). Interestingly, four of these antigens (HtrA, OmcB, IncA, and TC0651) also were capable of inducing antibody responses in human patients (Table S2) .
Combinations of Immunogenic Antigens Confer Additive Protection
Against Chlamydia Challenge. The data described so far indicate that 42 C. trachomatis proteins induce antibody-and/or cellmediated immune responses in natural and/or experimental infection (Table 1) . We next investigated whether some of these antigens elicited protective immunity in the intranasal model of mouse of C. muridarum infection. In particular, we focused our attention on 13 antigens (Table S4 ) that were recognized specifically by sera from Chlamydia-infected patients or that elicited CD4 + T cells included in the protective EB-specific T-cell line. BALB/c mice were immunized i.m. with randomly selected two-antigen combinations in the presence of the Th1 adjuvant LTK63+CpG (29, 30) . Two weeks after the last immunization, mice were given 10 3 EBs, and IFUs were counted in lung homogenates 10 d after challenge. For a primary screening, each combination was tested in at least 15 mice. Combinations giving a reduction in IFU count were tested in at least two repeated experiments (10-15 animals per group) to consolidate protection data. Among the tested combinations, Combo1 (TC0210+TC313), Combo3 (TC0106+TC0431), Combo4 (TC0551+TC0890), Combo5 (TC0660+TC0741), and Combo6 (TC0651+TC0727) showed a >0.9 log 10 reduction of IFU (P < 0.05) in the lungs of immunized mice (Table S4) .
Next, the five protective combinations were deconvoluted to establish the contribution of each individual antigen in protection. TC0210, TC0313, TC0106, TC0551, and TC0741 from Combo1, Combo3, Combo4, and Combo5, respectively, induced IFU reductions ranging from 0.5-0.9 log 10 (Table S4) . Three antigens (TC0106, TC0313, and TC0551) belong to the group of the CD4 + T-cell inducers; TC0741 elicits high antibody titers in infected humans, and TC0210 induces both types of response. Recently TC0741 has been shown to confer protective immunity against upper genital tract pathologies in mice (26), and we recently reported that TC0313 induces significant protection in DNA immunization experiments (22) .
Finally, we evaluated the protective activity of a four-antigen combination: TC0106, TC0210, TC0313, and TC0741 (Combo8). Two groups of 45 mice were immunized with either Combo8 or adjuvant alone, and the kinetics of bacterial clearance was followed at days 10, 12, and 14 after challenge in groups of 15 mice each. As shown in Fig. 3A , an IFU reduction of 4.1 log 10 was observed at day 12, corresponding to the peak of infection (P = 0.0001) (Table S4) . Furthermore, at day 12, 58% of immunized mice had no detectable Chlamydiae in the lungs, and this percentage increased to 82% at day 14. The protection level obtained with Combo8 suggests that robust immune responses can be elicited by combining partially protective antigens selected on the basis of their being immunogenic during infection. To support this additive effect, we also examined the protective activity of the four-antigen combination (Combo9) constituted by the four antigens (TC0106, TC0431, TC0551, and TC0890) present in Combo3 and Combo4. As shown in Fig. 3B , Combo9 immunization resulted in a 2.2 log 10 IFU reduction at day 12 postchallenge (P = 0.0003), roughly corresponding to the sum of protection levels obtained with Combo3 and Combo4 (Table  S4) . Because the four antigens included in Combo9 all belong to the group of antigens inducing CD4 + /IFN-γ + T-cells, we tested whether the observed protection was mediated by CD4 + T-cells. To this aim, mice were immunized with Combo9, and, immediately before challenge, CD4 + T cells were depleted by i.v. injection of a rat anti-mouse CD4 monoclonal antibody. As shown in Fig. 3C, CD4 + T-cell-depleted immunized mice were no longer protected, as indicated by the same IFU count being found in the lungs of Combo9-and adjuvant-immunized mice. No reduction in the protection level was observed when Combo9-immunized mice were injected with irrelevant rat Ig.
The presence of long-lasting effector memory cells is important for optimal Th1-mediated protection (31) . Therefore, we measured the frequency of CD3 + , CD4
+ antigen-specific IFN-γ-, IL-2-, and TNF-α-producing cells in peripheral blood mononuclear cells from mice immunized with Combo8 and Combo9 (Fig. S2) . Vaccination with the two protective antigen combinations induced a predominant frequency of multifunctional antigenspecific CD4 + T cells simultaneously producing IFN-γ/TNF-α or IFN-γ/TNF-α and IL-2. In particular, ∼20% of IFN-γ + cells also produced TNF-α and IL-2, and about 60% of them produced TNF-α. Overall, the Th1 cytokine profile of the antigen-specific CD4 + T cells suggests that vaccination with the four-antigen combos elicits T cells with functional properties that might be important for protection against intracellular pathogens.
Expression Analysis of Protective Antigens During Chlamydia Cell
Cycle. Finally, using Western blot analysis and confocal microscopy, we investigated the expression of the C. trachomatis orthologs (CT733, CT823, CT043, CT153, CT279, CT456, and CT601 respectively) of the seven C. muridarum antigens providing solid protection when properly combined in C. trachomatis EBs and reticulate bodies (RBs). Purified EBs (∼10 7 EBs) and Chlamydia-infected and noninfected HeLa cells (∼10 6 cells) were analyzed by Western blot. As shown in Fig. S3A , the seven proteins appeared to be expressed both in EB extracts and in infected cells 48 h after infection. We also investigated antigen cellular localization within infected HeLa cells by confocal microscopy at 24, 48, and 72 h postinfection. As shown in Fig. S3B , expression of all antigens was clearly detected within the inclusions 24 h postinfection and was still visible 72 h postinfection. Interestingly, CT153 (the TC0431 ortholog) encoding a protein belonging to the MAC-perforin family, whose components are capable of disrupting the cell membrane, appeared to accumulate at the level of the inclusion membrane. The other proteins were distributed homogeneously within the inclusion.
Discussion
Most infections induce immune responses that protect the individuals from subsequent exposures to the same infective agent. In the case of intracellular pathogens, such protective activity is mediated by a limited number of microbial components that elicit both cellular and humoral immunity. The challenge of vaccinology is to single out, among pathogen components, the ones that are immunogenic during infection and that induce protective responses. A number of high-throughput genomic and proteomic technologies have substantially improved our capacity to identify antibody-inducing antigens (4-7), but the search for antigens inducing cell-mediated responses has been more problematic thus far. In this work, using Chlamydia as model system, we show that genomic approaches are applicable to the discovery of T-cell antigens as well.
The first outcome of this work is its contribution to an atlas of chlamydial immunogenic proteins. Genome/proteome-based highthroughput technologies have been exploited recently to study Chlamydia immunogenic antigens (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Although the data are not always easily comparable because of the use of different strains, assays, and infected hosts (mice and humans), a Chlamydia immunome atlas can be compiled (Table S3) if one takes as reference the genome annotation of C. trachomatis and combines both mouse and human immunogenic antigens. From this atlas, it appears that, of the 901 proteins constituting the C. trachomatis proteome, 60% (544 proteins) have been tested for B-cell immunogenicity, and 35% (316 proteins) have been tested for T-cell immunogenicity. Overall, 85% of all immunogenic antigens induce either antibodies (33 antigens) or CD4 + T cells (37 antigens), but only 12 proteins were able to induce both antibodies and IFN-γ-producing CD4 + T cells (Table S3 ). At present, it is difficult to speculate on what makes an antigen an antibody inducer or a CD4 + /IFN-γ + T cell inducer. The existence of many T-cell antigens incapable of inducing antibody responses can be explained by their not being exposed on the EB surface; a more intriguing observation is the presence of many B-cell antigens that are invisible to T cells. However, the fact that the five antigens with bivalent function identified in this study belong to the category of well-expressed membrane proteins (Table 1 and  Table S4 ) seems to suggest that a level of expression and surface exposition are prerequisites for an antigen to stimulate both antibody and CD4 T-cell responses. One possible limitation of our approach is that it is biased by the a priori selection of specific categories of proteins. However, ∼25% of the proteins tested in this study for B-or T-cell immunogenicity were positive to the corresponding assay. [In other studies in which unbiased libraries were used (19, 20) the frequency of T-and B-cell antigens was <10%.] This result seems to suggest that the categories of proteins we selected are richer in immunogenic antigens.
A second outcome of this work is the identification of five antigens that had never before been shown to provide partial protection against Chlamydia. This result is unexpected because, apart from MOMP, no more than a dozen partially protective recombinant protein antigens had been described previously (14, 17, 32) .
The third outcome of this work is the demonstration that an additive effect can be achieved by combining partially protective antigens. Three pieces of evidence support this observation. First, when we combined four antigens, each reducing IFU counts in the lungs of challenged mice by ∼1 log 10 , robust protection was achieved. At day 12 after challenge, 58% of mice were Chlamydia free (below the detection limit of 500 IFUs) and the entire group of mice had a 4 log 10 decrease in Chlamydia infection. Second, when we combined two-protein combinations, each providing a IFU count reduction of ∼1.5 log 10 , a protection of 2.2 log 10 was obtained. Finally, in the course of our protective antigen screening based on two-antigen immunization, we identified a few protective combinations whose components were not protective when given alone. The additive effect observed in antigen combination is of particular interest for vaccine development and further supports the use of multiantigen formulations, which, as compared with single-antigen vaccines, have a reduced risk of favoring the selection of vaccine-resistant mutants. We have not yet tested all possible combinations of all antigens reported here, and we have not combined them with proteins previously reported to be protective. The progressive increase in protection seen with antigen addition suggests that such studies could lead to the formulation of a highly effective multicomponent vaccine. Although further optimization studies could be performed using our antigen combinations, we believe the four-antigen combinations described here are sufficiently protective to merit testing in humans, after a previous assessment of safety and immunogenicity in monkeys.
The selection of protective antigens was carried out using the mouse model of C. muridarum intranasal challenge. Several other models have been used to study chlamydial biology and immunology; these models include the mouse model of genital tract infection with human C. trachomatis strains, the mouse genital tract infection and infertility model with C. muridarum, the guinea pig model, and the two monkey models of trachoma and cervical infection (33) . Each model has its own advantages and disadvantages. For instance, infection of mice with C. trachomatis suffers the high susceptibility of the human strains to IFN-γ−mediated effector mechanisms developed in mice and usually requires hormonal treatment (34) . The C. muridarum mouse model of lower and upper genital tract infection followed by evaluation of infertility has the advantage of mimicking human disease but is laborious and not amenable to the analysis of a large number of vaccine candidates. Finally, the monkey models are very expensive and now are difficult to conduct for ethical reasons. The common denominator of all models studied thus far is that infection induces both IFN-γ-producing CD4 + T cells and antibodies whose elicitation correlates with protection data, when available. This characteristic leads us to predict that, when combined with proper Th1 adjuvants, protective antigens should be protective in most of the existing models. Experimental evidence supporting this prediction includes the demonstration that, when exposed to Chlamydia, pulmonary and genital mucosae induce very similar profiles of T-cell-mediated immunity (35) and that intranasal exposure to Chlamydia induces IFN-γ-secreting T cells confers protection to a subsequent intravaginal challenge (36) . Moreover, our protein array data with sera from human patients and from mice infected with either C. trachomatis or C. muridarum indicate the existence of overlapping profiles of antibody-inducing antigens. Nonetheless, because none of the existing models truly reproduces human infection, the effectiveness of an anti-Chlamydia vaccine ultimately can be determined only by proof-ofconcept efficacy trials in humans. As stated above, such trials are also required to prove the effectiveness of the four-antigen combinations described here.
It is generally accepted that chlamydial vaccines must induce a potent Th1 cell-mediated immunity to be protective. In this study, we used LTK63 and CpG as Th1 adjuvants because previously published work indicates that this mixture is effective in both mucosal and systemic immunization (37) . Our data confirm the Th1 character of LTK63+CpG: systemic immunization with all recombinant proteins induced good levels of antigen-specific CD4 + /IFN-γ + T cells, the majority of which also expressed IL-2 and/or TNF-α, thus establishing a reservoir of long-lasting effector memory cells (31) .
Although the LTK63+CpG combination performs well in our model, it would be interesting to analyze different Th1 adjuvants/ immunostimulators. Indeed, there are several examples in the Chlamydia field, showing that antigens, including the gold standard vaccine candidate MOMP, perform quite differently, in terms of protection, depending on the adjuvant used in immunization (38) (39) (40) .
The seven proteins included in the protective four-antigen combinations deserve a final comment. Apart from TARP, a protein able to interact with actin and probably involved in chlamydial invasion (41) , little is known about the roles of these proteins in Chlamydia biology. CT733/TC0106 is, thus far, an uncharacterized protein. CT601/TC0890 is an invasin with phosphatase activity containing a lysin domain, a feature often associated with peptidoglycan binding and bacterial cell wall degradation. CT279/TC0551 is a Na + -transporting NADH: ubiquinone oxidoreductase involved in the Na + chemiosmotic cycle and is proposed to participate in chlamydial adaptive mechanisms during infection, when the Na + and H + homeostasis of the host cell becomes severely impaired (42) . CT043/ TC0313 could act as a chaperone of an unknown substrate involved in the bacterial virulence, as postulated on the basis of its homology to other members of the CesT family (www.ncbi. nlm.nih.gov) (43) . CT823/TC0210 (HtrA) is a temperatureactivated serine endoprotease showing both chaperon and protease activities and probably is involved in chlamydial defense during conditions of high protein stress (44) . Finally, CT153/TC0431 belongs to the MAC/perforin family, a class of proteins performing critical functions in innate and adaptive immunity. Interestingly, CT153/TC0431 also shows high homology to Plasmodium Mac/perforin l, a protein involved in breaching the liver sinusoidal cell layer before hepatocyte infection (45) (46) (47) .
Human pathogens that reside within host cells and, like Chlamydia, induce natural immunity after infection include bacteria such as Salmonella, Shigella, Mycobacterium, and Yersinia, and parasites such as Leishmania (3, 31, (48) (49) (50) . Because immunity against these pathogens appears to be mediated by cellular and antibody responses, the approach described here could lead to the discovery of vaccines that have so far proved to be difficult to develop.
Materials and Methods
The high-throughput approaches used to define immunogenic B-and T-cell antigens are summarized in Fig. S1 . These approaches including selection and preparation of recombinant proteins, preparation of a protein array and immunoscreening with human and mice sera, screening of CD4-Th1 cell target antigens, protection in a mouse model of lung infection, and confocal microscopy analysis of protein expression (51, 22) . Specifications and further details are provided in SI Materials and Methods.
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